

Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Timolol / Dorzolamide Formulation

Manufacturer or supplier's details

Company name of supplier : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure

Category 1 (Cardio-vascular system, Central nervous system,

Gastrointestinal tract, Lungs)

GHS label elements

Hazard pictograms



Signal Word : Danger

Hazard Statements : H361d Suspected of damaging the unborn child.

H372 Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through pro-

longed or repeated exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapors. P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/

face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:



Timolol / Dorzolamide Formulation

Date of last issue: 04.04.2023 Version Revision Date: SDS Number: 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Dorzolamide	130693-82-2	>= 1 -< 5
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-	26921-17-5	>= 0.1 -< 1
morpholino-1,2,5-thiadiazole monomaleate		

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water. Suspected of damaging the unborn child.

Most important symptoms and effects, both acute and delayed

Causes damage to organs through prolonged or repeated

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing None known.



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

media

Specific hazards during fire

fighting

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulfur oxides Hydrogen chloride

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

Exposure to combustion products may be a hazard to health.

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

	<u> </u>				
Components	CAS-No.	Value type	Control parame-	Basis	
		(Form of	ters / Permissible		
		exposure)	concentration		
Dorzolamide	130693-82-2	TWA	10 μg/m3 (OEB 3)	Internal	
	Further information: Eye				
		Wipe limit	100 μg/100 cm ²	Internal	
(S)-3-[3-(tert-butylamino)-2- hydroxypropoxy]-4- morpholino-1,2,5-thiadiazole monomaleate	26921-17-5	TWA	10 μg/m3 (OEB 3)	Internal	
	Further information: Eye, Skin				
		Wipe limit	100 μg/100 cm ²	Internal	

Engineering measures: Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices).



Timolol / Dorzolamide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 5.9
 30.09.2023
 28815-00021
 Date of first issue: 06.11.2014

Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : colorless

Odor : No data available

Odor Threshold : No data available

pH : 5.6

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : 1.02

Density : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

Dorzolamide:

Acute oral toxicity : LD50 (Rat): 1,927 mg/kg

LD50 (Mouse): 1,320 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,140 mg/kg

Acute toxicity (other routes of:

administration)

LD50 (Mouse): 300 mg/kg

Application Route: Intraperitoneal

LD50 (Mouse): 800 mg/kg

Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Dorzolamide:

Species : Monkey

Result : Mild eye irritation

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species : Rabbit

Result : Mild eye irritation

Species : Dog

Result : No eye irritation



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Dorzolamide:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

Dorzolamide:

Genotoxicity in vitro : Test Type: Chromosomal aberration

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Cytogenetic assay

Species: Mouse Result: negative

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Method: OECD Test Guideline 474

Result: negative

Carcinogenicity

Not classified based on available information.



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Components:

Dorzolamide:

Species : Rat, male
Application Route : Oral
Exposure time : 2 Years

20 mg/kg body weight

Result : negative

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Species : Mouse Application Route : Oral

Exposure time : 21 month(s)
Result : negative

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 300 mg/kg body weight

Result : negative Target Organs : Adrenal gland

Remarks : The significance of these findings for humans is not certain.

Species : Mouse, female

Application Route : Oral Exposure time : 18 Months

LOAEL : 500 mg/kg body weight

Result : negative

Target Organs : Lungs, Mammary gland, Uterus (including cervix)

Remarks : The significance of these findings for humans is not certain.

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Dorzolamide:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 7.5 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight Early Embryonic Development: NOAEL F1: 150 mg/kg body

weight

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rabbit

Developmental Toxicity: LOAEL F1: 50 mg/kg body weight Result: Some evidence of adverse effects on development,

based on animal experiments.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

Product:

Target Organs : Cardio-vascular system, Central nervous system, Gastrointes-

tinal tract, Lungs

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Components:

Dorzolamide:

Target Organs : Central nervous system, Gastrointestinal tract, Bone, Blood,

Bladder

Assessment : May cause damage to organs through prolonged or repeated

exposure.

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Target Organs : Lungs, Cardio-vascular system

Assessment : Causes damage to organs through prolonged or repeated

exposure.



Timolol / Dorzolamide Formulation

Date of last issue: 04.04.2023 Version Revision Date: SDS Number: 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Repeated dose toxicity

Components:

Dorzolamide:

Species Rat **NOAEL** 0.05 mg/kg Application Route

Target Organs Bladder, Kidney

Species Dog

NOAEL 0.05 mg/kg LOAEL 2 mg/kg **Application Route** Oral Exposure time 1 y

Target Organs Gastrointestinal tract, Bone, Blood

Oral

Species Monkey NOAEL 0.05 mg/kg

Exposure time 1 y

Gastrointestinal tract, Bone, Blood **Target Organs**

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Rat **NOAEL** 25 mg/kg **Application Route** Oral Exposure time 67 Weeks

Species Dog NOAEL 10 mg/kg Application Route Oral Exposure time 54 Weeks **Target Organs** Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Product:

Eye contact Symptoms: The most common side effects are:, bitter taste,

burning or stinging of the eye, Blurred vision, Abdominal pain, Dizziness, digestive disorder, eye pain, Headache, hyperten-

sion, Nausea, upper respiratory tract infection

Components:

Dorzolamide:

Eye contact Symptoms: burning or stinging of the eye, Blurred vision, tear-

ing, asthenia, bitter taste, Nausea, dry mouth, Headache

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Symptoms: burning or stinging of the eye, dryness of the Eye contact

eyes, Headache, Nausea, Dizziness, dry mouth, changes in

libido, hair loss, Allergic reactions



Timolol / Dorzolamide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 5.9
 30.09.2023
 28815-00021
 Date of first issue: 06.11.2014

Ingestion : Symptoms: Headache, Fatigue, Respiratory disorders, Gas-

trointestinal discomfort, Allergic reactions, Rash, hair loss,

altered mental status, Dizziness, changes in libido

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Dorzolamide:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 699 mg/l

Exposure time: 48 h

Toxicity to microorganisms : EC50 (Natural microorganism): > 800 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 411 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 161 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

EC50 (Photobacterium phosphoreum): > 1,800 mg/l

Persistence and degradability

Components:

Dorzolamide:

Biodegradability : Result: not rapidly degradable

Biodegradation: 5 % Exposure time: 28 d

Method: OECD Test Guideline 314

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 0 % Exposure time: 30 d

Stability in water : Hydrolysis: 0 %(61 d)

Method: FDA 3.09



Timolol / Dorzolamide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 5.9
 30.09.2023
 28815-00021
 Date of first issue: 06.11.2014

Bioaccumulative potential

Components:

Dorzolamide:

Partition coefficient: n- :

octanol/water

log Pow: 0.292

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Partition coefficient: n-

octanol/water

: log Pow: 1.48

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5.9 30.09.2023 28815-00021 Date of first issue: 06.11.2014

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills.

: Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023 Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System: GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States): UN - United Nations: UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/



Timolol / Dorzolamide Formulation

VersionRevision Date:SDS Number:Date of last issue: 04.04.20235.930.09.202328815-00021Date of first issue: 06.11.2014

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX/Z8